Skip to main navigation Skip to search Skip to main content

Pediatric regulatory initiatives

Steven Hirschfeld*, Agnes Saint-Raymond

*Corresponding author for this work

Research output: Chapter in Book/Report/Conference proceedingChapterpeer-review

31 Scopus citations

Abstract

A series of government actions have evolved since the 1990s to facilitate the development of medicinal products for pediatric use using a combination of incentives and mandates. The initiatives have been successful in stimulating activity and interest in products developed for pediatric use. The initiatives continue to evolve as experience accumulates and regulatory agencies develop robust cooperative programs. A multidimensional program is necessary to achieve the necessary goal of aligning pediatric therapeutics with adult therapeutics and providing children the most favorable opportunity to benefit and minimize risk to vulnerable populations.

Original languageEnglish
Title of host publicationPediatric Clinical Pharmacology
EditorsHannsjorg Seyberth, Hannsjorg Seyberth, Matthias Schwab, Matthias Schwab, Anders Rane
Pages245-268
Number of pages24
DOIs
StatePublished - 2011

Publication series

NameHandbook of Experimental Pharmacology
Volume205
ISSN (Print)0171-2004
ISSN (Electronic)1865-0325

Keywords

  • Deferrals
  • European Pediatric Regulation
  • ICH E11 guidelines
  • Pediatric investigation plan
  • Pediatric medicines
  • Pediatric rules
  • Therapeutic orphans
  • United States Federal Pediatric Initiatives
  • Waivers
  • Written request

Cite this